Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy

BACKGROUND: Systemic Lutetium-177 prostate-specific membrane antigen-617 radioligand therapy (Lu-177-PSMA-617-RLT) is a novel treatment approach in patients suffering from metastasized castration-resistant prostate cancer. Nonetheless, a therapeutic response may fail to appear in a proportion of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wrenger, Robin, Jüptner, Michael, Marx, Marlies, Zhao, Yi, Zuhayra, Maaz, Caliebe, Amke, Osmonov, Daniar, Lützen, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254582/
https://www.ncbi.nlm.nih.gov/pubmed/35788220
http://dx.doi.org/10.1186/s12894-022-01050-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254582/
https://www.ncbi.nlm.nih.gov/pubmed/35788220
http://dx.doi.org/10.1186/s12894-022-01050-3

Ejemplares similares